BioSpace News Archive

Victa Biotherapeutics is a new open-innovation joint venture designed to further validate Dr. Sukhatme’s pioneering immuno-oncology research in precision medicine applications

Analysis of data expected in early 2019

Promotes Prahlad Singh to lead newly created role

The completion of this investment was notably subject to the obtention of Chinese regulatory authorizations and to the visa of the French financial markets authority on the prospectus related to the Share Capital Increase.

Company Also Receives European CE Mark Approval for Novel Stroke Technology Designed for Difficult to Extract Blood Clots

OncoSec Medical Incorporated announced today that the Company has received a $7.0 million investment at $1.50 per share from Alpha Holdings, Inc. (kosdaq:117670) as part of a fundamental strategic investment centered on the clinical development of OncoSec’s lead immunotherapy product candidate, TAVO™ (tavokinogene telseplasmid).

The FCS Foundation, the nation’s leading advocacy and support organization for people affected by familial chylomicronemia syndrome (FCS), today announced the launch of a new national campaign to build broader awareness of the need for a treatment for FCS and to encourage regulators and leaders in research to work to bring a treatment to patients as quickly as possible.

Data-sharing results in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results.

ORHub, Inc. today announces that Blake Stock, Senior Director of Product will present at the AORN of Seattle’s Annual Multi-chapter Conference on Saturday, January 26, 2019 at 10:50AM PST. The conference is being held at the Valley Medical Center in Renton, Washington.

Funding received from the Bill & Melinda Gates Foundation